Vimarsana
Biggest News Aggregation in the World

Baseline Over News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Baseline Over. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Baseline Over Today - Breaking & Trending Today

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures - Vimarsana News

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Published: May 1, 2023

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative... | April 30, 2023

Source: marketscreener.com
Related Topics:
Lisah LancasterToby MaherChristopher KeenanLos AngelesDrug AdministrationBexotegrast Clinical Development NextUniversity Of Southern CaliforniaCorporate CommunicationsVanderbilt University Medical CenterPliant Therapeutics IncEuropean Medicines AgencyGroup Demonstrated Treatment Effects Including Durable ImprovementsQuantitative Lung FibrosisWell ToleratedPercent ChangeCough Severity Visual Analog ScaleBaseline OverChief Medical OfficerForced Vital CapacityIdiopathic PulmonaryInterstitial Lung DiseaseKeck SchoolSouthern CaliforniaPliant TherapeuticsPrivate Securities Litigation Reform Act
Pliant Therapeutics Announces Positive Long-Term Data from - Vimarsana News

Pliant Therapeutics Announces Positive Long-Term Data from

Published: April 30, 2023

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care...

Source: globenewswire.com
Related Topics:
Lisah LancasterToby MaherLos AngelesChristopher KeenanGroup Demonstrated Treatment Effects Including Durable ImprovementsCorporate CommunicationsDrug AdministrationVanderbilt University Medical CenterEuropean Medicines AgencyBexotegrast Clinical Development NextPliant Therapeutics IncUniversity Of Southern CaliforniaQuantitative Lung FibrosisWell ToleratedPercent ChangeCough Severity Visual Analog ScaleBaseline OverChief Medical OfficerForced Vital CapacityIdiopathic PulmonaryInterstitial Lung DiseaseKeck SchoolSouthern CaliforniaPliant TherapeuticsPrivate Securities Litigation Reform Act
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures - Vimarsana News

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Published: April 30, 2023

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative... | April 30, 2023

Source: marketscreener.com
Related Topics:
Lisah LancasterChristopher KeenanLos AngelesToby MaherDrug AdministrationBexotegrast Clinical Development NextCorporate CommunicationsGroup Demonstrated Treatment Effects Including Durable ImprovementsKeck School Of MedicineVanderbilt University Medical CenterUniversity Of Southern CaliforniaGlobenewswire IncPliant Therapeutics IncEuropean Medicines AgencyQuantitative Lung FibrosisWell ToleratedPercent ChangeCough Severity Visual Analog ScaleBaseline OverChief Medical OfficerForced Vital CapacityIdiopathic PulmonaryInterstitial Lung DiseaseSouthern CaliforniaPliant Therapeutics